External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

<ul><li>Product sales continued beating expectations. In 2Q24, BeiGene recorded total product sales of US$921mn (+23% QoQ, +66% YoY).</li><li>The 1H24 total product sales reached US$1.67bn, representing 51.4% of our previous FY24 estimate, beating our expectations.</li><li>Zanubrutinib (zanu) maintained strong sales momentum, increasing 30% QoQ or 107% YoY to US$637mn. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Product sales continued beating expectations. In 2Q24, BeiGene recorded total product sales of US$921mn (+23% QoQ, +66% YoY).The 1H24 total product sales reached US$1.67bn, representing 51.4% of our previous FY24 estimate, beating our expectations.Zanubrutinib (zanu) maintained strong sales momentum, increasing 30% QoQ or 107% YoY to US$637mn. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

BeiGene (BGNE US) - Sales Exceeding Expectations and Achieving Non-GAAP Profitability

<ul><li>Product sales continued beating expectation. In 1Q24, BeiGene recorded total product sales of US$747mn (+18% QoQ, +82% YoY), representing 25.7% of our previous FY24 estimate.</li><li>Zanubrutinib (zanu) maintained strong sales momentum, with sales increasing 18% QoQ or 131% YoY to US$489mn.</li><li>The strong performance of zanu was driven by market share gain in CLL in the US and the expansion of reimbursement coverage in the EU. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Product sales continued beating expectation. In 1Q24, BeiGene recorded total product sales of US$747mn (+18% QoQ, +82% YoY), representing 25.7% of our previous FY24 estimate.Zanubrutinib (zanu) maintained strong sales momentum, with sales increasing 18% QoQ or 131% YoY to US$489mn.The strong performance of zanu was driven by market share gain in CLL in the US and the expansion of reimbursement coverage in the EU. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

BeiGene (BGNE US) - Consistently Exceeding Expectations

<ul><li>Strong sales momentum of zanubrutinib eased market concerns. In 4Q23, BeiGene recorded total product sales of US$631mn (+6% QoQ or +86% YoY).</li><li>Zanubrutinib (zanu) maintained strong sales momentum, with revenue increasing 15% QoQ or 135% YoY to US$413mn, mainly driven by market share gains in the US.</li><li>In 4Q23, zanu sales in the US increased 16% QoQ to US$313mn, contributing 76% of zanu’s global sales. I</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Strong sales momentum of zanubrutinib eased market concerns. In 4Q23, BeiGene recorded total product sales of US$631mn (+6% QoQ or +86% YoY).Zanubrutinib (zanu) maintained strong sales momentum, with revenue increasing 15% QoQ or 135% YoY to US$413mn, mainly driven by market share gains in the US.In 4Q23, zanu sales in the US increased 16% QoQ to US$313mn, contributing 76% of zanu’s global sales. IContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

BeiGene (BGNE US) – Expect a Productive 2024 for Early Pipeline Assets

<ul><li>Zanubrutinib continued to show PFS superiority vs ibrutinib with longer follow-up.</li><li>Sonrotoclax (BCL2i) could be a game changer.</li><li>BTK-CDAC to solve the BTKi-resistant issues.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Zanubrutinib continued to show PFS superiority vs ibrutinib with longer follow-up.Sonrotoclax (BCL2i) could be a game changer.BTK-CDAC to solve the BTKi-resistant issues.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

BeiGene (BGNE US) – Three Synergistic Haematology BIC/FIC Molecules Showing Promising Data

<ul><li>Strong sales of zanubrutinib continued. In 3Q23, BeiGene recorded product sales of US$595mn (+8% QoQ or +70% YoY).</li><li>Zanubrutinib (zanu) maintained a strong sales momentum, with revenue increasing 16% QoQ or 130% YoY to US$358mn in 3Q23 (vs +46% QoQ growth in 2Q23), mainly driven by sales growth in the US.</li><li>In 3Q23, zanu sales in the US increased 21% QoQ to US$270mn (vs +61% QoQ in 2Q23), thanks to the continuous adoption among CLL/SLL patients. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Strong sales of zanubrutinib continued. In 3Q23, BeiGene recorded product sales of US$595mn (+8% QoQ or +70% YoY).Zanubrutinib (zanu) maintained a strong sales momentum, with revenue increasing 16% QoQ or 130% YoY to US$358mn in 3Q23 (vs +46% QoQ growth in 2Q23), mainly driven by sales growth in the US.In 3Q23, zanu sales in the US increased 21% QoQ to US$270mn (vs +61% QoQ in 2Q23), thanks to the continuous adoption among CLL/SLL patients. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

BeiGene (BGNE US) – Strong Sales Momentum Continued in 3Q

Switzerland

BeOne Medicines is a global oncology biotechnology company focused on the discovery, development, and commercialization of cancer medicines. Its portfolio includes commercial-stage products like BRUKINSA, TEVIMBRA, and PARTRUVIX, which target various blood cancers and solid tumors. The company was founded in 2010 and is headquartered in Basel, Switzerland.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BeOne Medicines (6160 HK)

BeiGene (BGNE US) - Sales Exceeding Expectations and Achieving Non-GAAP Profitability

Product sales continued beating expectations. In 2Q24, BeiGene recorded total product sales of US$921mn (+23% QoQ, +66% YoY).

CMB International

BeiGene (BGNE US) - Consistently Exceeding Expectations

Product sales continued beating expectation. In 1Q24, BeiGene recorded total product sales of US$747mn (+18% QoQ, +82% YoY), representing 25.7% of...

CMB International

BeiGene (BGNE US) – Expect a Productive 2024 for Early Pipeline Assets

Strong sales momentum of zanubrutinib eased market concerns. In 4Q23, BeiGene recorded total product sales of US$631mn (+6% QoQ or +86% YoY).

CMB International

BeiGene (BGNE US) – Three Synergistic Haematology BIC/FIC Molecules Showing Promising Data

Additional studies presented at ASH indicated that zanu provided meaningful benefits for acalabrutinib-intolerant patients, which could lead to...

CMB International

BeiGene (BGNE US) – Strong Sales Momentum Continued in 3Q

In 3Q23, zanu sales in the US increased 21% QoQ to US$270mn (vs +61% QoQ in 2Q23), thanks to the continuous adoption among CLL/SLL patients.

CMB International

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)